Abstract:Background Proline-rich tyrosine kinase 2 (Pyk2) is essential in neutrophil degranulation and chemotaxis in vitro. However, its effect on the process of lung inflammation and edema formation during LPS induced acute lung injury (ALI) remains unknown. The goal of the present study was to determine the effect of inhibiting Pyk2 on LPS-induced acute lung inflammation and injury in vivo. Methods C57BL6 mice were given either 10 mg/kg LPS or saline intratracheally. Inhibition of Pyk2 was effected by intraperitoneal administration TAT-Pyk2-CT 1 h before challenge. Bronchoalveolar lavage analysis of cell counts, lung histology and protein concentration in BAL were analyzed at 18 h after LPS treatment. KC and MIP-2 concentrations in BAL were measured by a mouse cytokine multiplex kit. The static lung compliance was determined by pressure-volume curve using a computer-controlled small animal ventilator. The extravasated Evans blue concentration in lung homogenate was determined spectrophotometrically. Results Intratracheal instillation of LPS induced significant neutrophil infiltration into the lung interstitium and alveolar space, which was attenuated by pre-treatment with TAT-Pyk2-CT. TAT-Pyk2-CT pretreatment also attenuated 1) myeloperoxidase content in lung tissues, 2) vascular leakage as measured by Evans blue dye extravasation in the lungs and the increase in protein concentration in bronchoalveolar lavage, and 3) the decrease in lung compliance. In each paradigm, treatment with control protein TAT-GFP had no blocking effect. By contrast, production of neutrophil chemokines MIP-2 and keratinocyte-derived chemokine in the bronchoalveolar lavage was not reduced by TAT-Pyk2-CT. Western blot analysis confirmed that tyrosine phosphorylation of Pyk2 in LPS-challenged lungs was reduced to control levels by TAT-Pyk2-CT pretreatment. Conclusions These results suggest that Pyk2 plays an important role in the development of acute lung injury in mice and that pharmacological inhibition of Pyk2 might provide a potential therapeutic strategy in the pretreatment for patients at imminent risk of developing acute lung injury.

Pivotal Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Inflammatory Pulmonary Diseases

Regulation of Mitogen-Activated Protein Kinase Activated Protein Kinase-2 on Expression of Important Inflammatory Mediators in Acute Lung Injury

Remodeling Tumor-Associated Macrophage for Anti-Cancer Effects by Rational Design of Irreversible Inhibition of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2

MK2 Mediates Macrophage Activation and Acute Lung Injury by Regulating Let-7E Mirna

Role and regulation of MKP-1 in airway inflammation

AKT2 Regulates Pulmonary Inflammation and Fibrosis Via Modulating Macrophage Activation

Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies

Targeting MAPK signaling: A promising approach for treating inflammatory lung disease

A Role for MK2 in Enhancing Neutrophil-Derived ROS Production and Aggravating Liver Ischemia/Reperfusion Injury

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

MK2 Posttranscriptionally Regulates TNF-α-induced Expression of ICAM-1 and IL-8 Via Tristetraprolin in Human Pulmonary Microvascular Endothelial Cells.

Map Kinase Phosphatase 5 Protects Against Sepsis-Induced Acute Lung Injury

Functional Roles of p38 Mitogen-Activated Protein Kinase in Macrophage-Mediated Inflammatory Responses

Inhibition of Pyk2 Blocks Lung Inflammation and Injury in a Mouse Model of Acute Lung Injury

MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution

MKP1 Regulates the Induction of Inflammatory Response by Pneumococcal Pneumolysin in Human Epithelial Cells

P38 Mitogen Activated Protein Kinase and Chronic Airway Disease

Increased Activity of MAPKAPK2 within Mesenchymal Cells as a Target for Inflammation-Associated Fibrosis in Crohn’s Disease

Interactive Roles of CaMKII/Ryanodine Receptor Signaling and Inflammation in Lung Diseases

P38 Mitogen-activated Protein Kinase and Hematologic Malignancies.

MAPKAPK2 (MK2) Facilitates the Epithelial-Mesenchymal Transition in Lung Adenocarcinoma Through Activation of the AKT/MYC Signaling Pathway